Cellular based treatment modalities for unresectable hepatocellular carcinoma

doi:10.5306/wjco.v12.i5.290

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8267)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

576

WORD

190

HTML

4407

Figures (1-1)

355

Tables (1-3)

344

Sum=5872

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

320

Download

701

Sum=1021

Publishing Process of This Article

Item

Count

Browse

449

Download

929

Sum=1378

May 24, 2021 (publication date) through Feb 14, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. May 24, 2021; 12(5): 290-308
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.290

Table 2 Ongoing clinical trials investigating T cell receptor engineered T cells in the treatment of hepatocellular carcinoma according to ClinicalTrials.gov

Product/target	Phase	Estimated completion	Study/identifier
C-TCR055/AFP	I	April 2021	NCT03971747
C-TCR055/AFP	I	November 2021	NCT04368182
HBV-TCR T cell/HBV Ag	I	June 2024	NCT03899415
IMA202-101/MAGE A1	I	June 2024	NCT03441100
AFP T cells/AFP	I	June 2026	NCT03132792

AFP: Alpha fetoprotein; HBV: Hepatitis B virus; Ag: Antigen; MAGE: Melanoma antigen gene protein.

Citation: Damiris K, Abbad H, Pyrsopoulos N. Cellular based treatment modalities for unresectable hepatocellular carcinoma. World J Clin Oncol 2021; 12(5): 290-308
URL: https://www.wjgnet.com/2218-4333/full/v12/i5/290.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i5.290